<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 71.1</label>
 <caption>
  <p>Representative studies of M2 inhibitor susceptibility of influenza A field isolates from adults and children</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>Site</th>
    <th>Period</th>
    <th>Method</th>
    <th>No. tested by subtype</th>
    <th>No. (%) resistant</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="2">Belshe et al. [
     <xref ref-type="bibr" rid="CR24">24</xref>]
    </td>
    <td rowspan="2">United States</td>
    <td rowspan="2">1978–1988</td>
    <td rowspan="2">EIA, S</td>
    <td>65 H1N1</td>
    <td>0</td>
   </tr>
   <tr>
    <td>181 H3N2</td>
    <td>5 (2.0 %)
     <sup>a</sup>
    </td>
   </tr>
   <tr>
    <td rowspan="2">Valette et al. [
     <xref ref-type="bibr" rid="CR202">202</xref>]
    </td>
    <td rowspan="2">France</td>
    <td rowspan="2">1988–1990</td>
    <td rowspan="2">EIA</td>
    <td>28 H1N1</td>
    <td>0</td>
   </tr>
   <tr>
    <td>77 H3N2</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Ziegler et al. [
     <xref ref-type="bibr" rid="CR203">203</xref>]
    </td>
    <td>43 countries</td>
    <td>1991–1995</td>
    <td>EIA, S, PCR-RFLP</td>
    <td>2017</td>
    <td>16 (0.8 %)
     <sup>b</sup>
    </td>
   </tr>
   <tr>
    <td>Dawson [
     <xref ref-type="bibr" rid="CR204">204</xref>]
    </td>
    <td>UK</td>
    <td>1968–1999</td>
    <td>EIA, plaque</td>
    <td>1813</td>
    <td>28 (1.5 %)</td>
   </tr>
   <tr>
    <td rowspan="2">Suzuki et al. [
     <xref ref-type="bibr" rid="CR205">205</xref>]
    </td>
    <td rowspan="2">Japan</td>
    <td>1993–1998</td>
    <td>Not stated</td>
    <td>55</td>
    <td>0</td>
   </tr>
   <tr>
    <td>1999–2000</td>
    <td>Not stated</td>
    <td>179</td>
    <td>6 (3.4 %)</td>
   </tr>
   <tr>
    <td>Shih et al. [
     <xref ref-type="bibr" rid="CR206">206</xref>]
    </td>
    <td>Taiwan</td>
    <td>1996–1998</td>
    <td>Plaque, S</td>
    <td>84</td>
    <td>1(1.2 %)</td>
   </tr>
   <tr>
    <td rowspan="6">Bright et al. [
     <xref ref-type="bibr" rid="CR38">38</xref>]
    </td>
    <td rowspan="6">Global</td>
    <td>1994–2005</td>
    <td rowspan="6">S</td>
    <td>6525</td>
    <td>392 (6.0 %)</td>
   </tr>
   <tr>
    <td>1994–2002</td>
    <td rowspan="4">H3N2</td>
    <td rowspan="2">0.3–1.8 %</td>
   </tr>
   <tr>
    <td rowspan="2">2003–2005</td>
   </tr>
   <tr>
    <td rowspan="2">12.3–13.3 %
     <sup>c</sup>
    </td>
   </tr>
   <tr>
    <td rowspan="2">1998–2004</td>
   </tr>
   <tr>
    <td>589 H1N1</td>
    <td>2 (0.3 %)</td>
   </tr>
   <tr>
    <td rowspan="2">Bright et al. [
     <xref ref-type="bibr" rid="CR29">29</xref>]
    </td>
    <td rowspan="2">United States</td>
    <td rowspan="2">2005</td>
    <td rowspan="2">S</td>
    <td>205 H3N2</td>
    <td>193 (92.3 %)</td>
   </tr>
   <tr>
    <td>8 H1N1</td>
    <td>2 (25 %)</td>
   </tr>
   <tr>
    <td rowspan="2">Saito et al. [
     <xref ref-type="bibr" rid="CR207">207</xref>]
    </td>
    <td rowspan="2">Japan</td>
    <td rowspan="2">2005–2006</td>
    <td rowspan="2">S</td>
    <td>354 H3N2</td>
    <td>231 (65.3 %)</td>
   </tr>
   <tr>
    <td>61 H1N1</td>
    <td>0</td>
   </tr>
   <tr>
    <td rowspan="2">Barr et al. [
     <xref ref-type="bibr" rid="CR43">43</xref>]
    </td>
    <td rowspan="2">Australia, New Zealand, Asia, South Africa</td>
    <td rowspan="2">2005</td>
    <td rowspan="2">S</td>
    <td>102 H3N2</td>
    <td>43 (42 %)</td>
   </tr>
   <tr>
    <td>37 H1N1</td>
    <td>0</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Abbreviations</italic>: 
   <italic>S</italic> M2 gene sequence analysis, 
   <italic>PCR-RFLP</italic> polymerase chain reaction-restriction length polymorphism, 
   <italic>EIA</italic> enzyme immunoassay
  </p>
  <p>
   <sup>a</sup>All resistant viruses from family members receiving rimantadine
  </p>
  <p>
   <sup>b</sup>Over 80 % of tested isolates were H3N2 subtype and all resistant ones were of this subtype. Separate analysis found that 9 (4.5 %) of 198 strains from Australia, 1989–1995, were resistant
  </p>
  <p>
   <sup>c</sup>In 2004–2005 the frequencies of resistance in H3N2 viruses were 73.8 % in China, 69.6 % in Hong Kong, 22.7 % in Taiwan, 15.1 % in South Korea, 4.3 % in Japan, 30.0 % in Canada, 19.2 % in Mexico, 14.5 % in United States, and 4.7 % in Europe
  </p>
 </table-wrap-foot>
</table-wrap>
